治疗性脂肪体组合,以增强化疗反应和瘤微环境的免疫激活
Zili Gu1, Jie Yin2, Candido G Da Silva1
1Department of Radiology, Leiden University Medical Center, the Netherlands.
概括
这项研究结合了oxaliplatin化疗与使用脂质体克服药物耐药性的收费类受体 (TLR) 激动剂. 这种新的方法可以增强抗瘤免疫力,并通过重编程瘤微环境来减少瘤生长.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 纳米技术 纳米技术
背景情况:
- 奥克萨利普拉丁化疗可以诱导免疫抑制瘤微环境,其特点是M2巨细胞增加和细胞毒性T细胞减少,导致治疗耐药性.
- 收费类受体 (TLR) 激动剂可以触发炎症反应,潜在地抵消氧沙胺耐药性并增强抗瘤功效.
研究的目的:
- 在临床前模型中研究TLR激动剂和氧沙对巨细胞功能,抗瘤T细胞免疫力和瘤生长控制的联合作用.
- 评估脂质体输送系统,用于同时输送氧沙和TLR激动剂 (Poly I:C和R848),以增强免疫激活和最小化副作用.
主要方法:
- 建立带有结直肠瘤的斑马鱼和小鼠模型.
- 使用中性脂质体进行氧化的输送,并使用阴性脂质体进行TLR激动剂 (Poly I:C和R848) 的联合输送.
- 在体外评估脂肪体系统的物理化学特性和生物活动.
- 评估了对巨细胞群,树突细胞成熟,T细胞透和瘤生长的体内影响.
主要成果:
- 脂质体输送系统表现出有利的物理化学特性和体外生物活动.
- 组合疗法在斑马鱼和小鼠模型中显著增强了瘤回归.
- 接受治疗的动物显示M2巨细胞数量减少,树突细胞数量增加,DC成熟度增强,T细胞透率增加.
- 这些免疫变化与治疗瘤中的免疫细胞死亡诱导有关.
结论:
- 氧沙和TLR激动剂的脂质体共递是克服氧沙耐药性的有希望的策略.
- 这种组合疗法有效地将瘤微环境重新编程为一种抗瘤免疫状态.
- 这些发现为开发改进的癌症治疗策略提供了宝贵的见解,这些策略可以增强免疫反应.
更多相关视频
09:56Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
14.9K
07:47Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance
Published on: December 13, 2015
9.0K
相关概念视频
01:27Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K